Floatz Rating
C34/100
Confidence
Indicative
Sponsor
Andrew Hendifar, MD
Modality
Small molecule
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05336266CT.gov A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Ductal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ketorolac (this asset) | Andrew Hendifar, MD | Early P1 | C · 34 |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| Daraxonrasib | Revolution Medicines, Inc. | P3 | BB |
| Rmc-6236 | Tango Therapeutics, Inc. | P3 | BB |
| Fluorouracilum | Jonsson Comprehensive Cancer Center | P3 | B |
| Capecitabine | Shenyang Sunshine Pharmaceutical Co., LTD. | P3 | B |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | OHSU Knight Cancer Institute | P2 | B |
| (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone | Corcept Therapeutics | P3 | B |
| Durvalumab | Jonsson Comprehensive Cancer Center | P2 | B |
+42 more in the Pancreatic Ductal Adenocarcinoma cohort
Other indications for Ketorolac
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Migraine Disorder | — | P4 | BBB · 72 |
| Breast Cancer | — | P4 | BB · 66 |
| Substance-Related Disorder | — | P3 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ketorolac in Pancreatic Ductal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ketorolac-pancreatic-ductal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →